



JC02R... PCT/PTO 13 MAY 2002

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weitz

Serial No: 10/019,325

Filed: December 21, 2001

For: Heparin Compositions that Inhibit Clot
Associated Coagulation Factors

Art Unit: Not yet assigned

Attorney Document No.: GDV-001.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231, on May 3, 2002.


Kristen Willett

RESPONSE TO NOTICE OF MISSING REQUIREMENTS

Box Missing Parts
Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

In response to the Notice of Missing Requirements dated March 8, 2002, Applicants submit herewith a check totaling \$130.00. Also enclosed is a copy of the executed declaration that we filed on February 11, 2002; a copy of the stamped postcard showing that the declaration was received at the PTO on February 27, 2002; and a copy of the Notice of Missing Requirements.


The Notice also requires a copy of the "Sequence Listing" in computer readable form. Applicants respectfully submit that this application does not require submission of a Sequence Listing, under C.F.R. 1.821(e) only applications which contain disclosures of nucleotide and/or amino acid sequences require a copy of the sequence listing. This application does not contain disclosures of nucleotide and/or amino acid sequences. Accordingly, there is no sequence to submit.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our Deposit Account No. 06-1448.

Respectfully Submitted,

Date: May 3, 2002

Customer No: 25181
Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170



Anita Varma
Reg. No. 43,221

05/20/2002 001111 00000000 10019325

01 001111 130.00 00



Appln. Serial No. 10/019,325
Filed: December 21, 2001

Atty Docket No.: GDV-001.01
(18403-101)

Applicants: Jeffrey I. Weitz

Title: **Heparin Compositions That Inhibit Clot Associated Coagulation Factors**

The following was/were received in the U.S. Patent & Trademark Office Mail Room on the date stamped hereon:

1. Transmittal Form (1 page)
2. An executed Declaration for Patent Application (2 pages)
3. This return receipt postcard

Atty: Anita Varma

Mailing Date: February 11, 2002
First Class Mailing (37 CFR 1.8(a))

Appln. Serial No. 10/019,325
Filed: December 21, 2001

Atty Docket No.: GDV-001.01
(18403-101)

Applicants: Jeffrey I. Weitz

Title: **Heparin Compositions That Inhibit Clot Associated Coagulation Factors**

The following was/were received in the U.S. Patent & Trademark Office Mail Room on the date stamped hereon:

1. Transmittal Form (1 page)
2. An executed Declaration for Patent Application (2 pages)
3. This return receipt postcard

Atty: Anita Varma

Mailing Date: February 11, 2002
First Class Mailing (37 CFR 1.8(a))

JC20 Rec'd PCT/PTO 27 FEB 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20503
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/019,325	Jeffrey I. Weitz	GDV-001.01

INTERNATIONAL APPLICATION NO.

PCT/CA00/00774

FILA FILING DATE

PRIORITY DATE

06/29/2000

06/30/1999

 25181
 FOLEY, HOAG & ELIOT, LLP
 PATENT GROUP
 ONE POST OFFICE SQUARE
 BOSTON, MA 02109

Missing Requirements w/ Seq Listing
DUE: 5.8.02
FINAL: 10.8.02

CONFIRMATION NO. 6259

371 FORMALITIES LETTER



OC000000007563450

Date Mailed: 03/08/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

RECEIVED

MAR 18 2002

PATENT DEPT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$130** for a Large Entity:

- **\$130** Late oath or declaration Surcharge.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

• BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.

10/019,325

INTERNATIONAL APPLICATION NO.

PCT/CA00/00774

ATTY. DOCKET NO.

GDV-001.01

FORM PCT/DO/EO/905 (371 Formalities Notice)